Trial Profile
Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Head and neck cancer; Mouth neoplasm; Precancerous conditions; Squamous cell cancer
- Focus Therapeutic Use
- 08 Jan 2021 Status changed from active, no longer recruiting to completed.
- 06 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.